Bryan L. Roth mainly focuses on Receptor, Neuroscience, Pharmacology, G protein-coupled receptor and 5-HT receptor. His Receptor study is focused on Biochemistry in general. Bryan L. Roth combines subjects such as Schizophrenia and Serotonin with his study of Neuroscience.
His Pharmacology study combines topics in areas such as Antidepressant, Mechanism of action, Atypical antipsychotic and Partial agonist. His work focuses on many connections between G protein-coupled receptor and other disciplines, such as Rhodopsin-like receptors, that overlap with his field of interest in Protein engineering. His 5-HT receptor research integrates issues from Endocrinology, Serotonergic and Anxiety.
Bryan L. Roth spends much of his time researching Receptor, Pharmacology, Stereochemistry, G protein-coupled receptor and Agonist. His Receptor research incorporates elements of Signal transduction and Neuroscience. His Pharmacology research is multidisciplinary, incorporating elements of Clozapine, Atypical antipsychotic, Dopamine receptor D2, Opioid and In vivo.
His Stereochemistry research is multidisciplinary, relying on both Salvinorin A, Structure–activity relationship, Chemical synthesis and Binding site. He interconnects Computational biology and G protein in the investigation of issues within G protein-coupled receptor. His work carried out in the field of 5-HT receptor brings together such families of science as Endocrinology, Antagonist and Serotonergic.
The scientist’s investigation covers issues in Receptor, Pharmacology, G protein-coupled receptor, Neuroscience and Agonist. His Receptor study combines topics from a wide range of disciplines, such as Stereochemistry and Cell biology. His Pharmacology study incorporates themes from Antagonist, 5-HT receptor, Opioid, Prepulse inhibition and In vivo.
His work deals with themes such as Computational biology, Allosteric regulation and Ligand, which intersect with G protein-coupled receptor. His study in the field of Dopamine, Dopamine receptor and Chemogenetics also crosses realms of Structure and function. As a part of the same scientific study, Bryan L. Roth usually deals with the Agonist, concentrating on Muscarinic acetylcholine receptor and frequently concerns with Low dose and Cell signaling.
His main research concerns Receptor, G protein-coupled receptor, Neuroscience, Pharmacology and Computational biology. The Receptor study combines topics in areas such as Melatonin and Cell biology. His work in G protein-coupled receptor addresses subjects such as Hallucinogen, which are connected to disciplines such as Structural biology.
His Neuroscience research includes elements of κ-opioid receptor and Function. His studies in Pharmacology integrate themes in fields like Dopaminergic, Endogenous agonist and In vivo. His biological study spans a wide range of topics, including Human genome, Human physiology, Comparative genomics, Druggability and Drug discovery.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
David E. Gordon;Gwendolyn M. Jang;Mehdi Bouhaddou;Jiewei Xu.
Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression
Grazyna Rajkowska;José J Miguel-Hidalgo;Jinrong Wei;Ginny Dilley.
Biological Psychiatry (1999)
Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand
Blaine N. Armbruster;Xiang Li;Mark H. Pausch;Stefan Herlitze.
Proceedings of the National Academy of Sciences of the United States of America (2007)
Relating protein pharmacology by ligand chemistry
Michael J. Keiser;Bryan L. Roth;Bryan L. Roth;Blaine N. Armbruster;Paul R Ernsberger.
Nature Biotechnology (2007)
Predicting new molecular targets for known drugs
Michael J. Keiser;Vincent Setola;John J. Irwin;Christian Laggner.
The expanded biology of serotonin.
Miles Berger;John A. Gray;Bryan L. Roth.
Annual Review of Medicine (2009)
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
Jonathan D. Urban;William P. Clarke;Mark Von Zastrow;David E. Nichols.
Journal of Pharmacology and Experimental Therapeutics (2007)
Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
Bryan L. Roth;Douglas J. Sheffler;Wesley K. Kroeze.
Nature Reviews Drug Discovery (2004)
Rapid, reversible activation of AgRP neurons drives feeding behavior in mice
Michael J. Krashes;Shuichi Koda;Chian Ping Ye;Sarah C. Rogan.
Journal of Clinical Investigation (2011)
Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.
David A. Shapiro;Sean Renock;Elaine Arrington;Louis A. Chiodo.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: